Jolkinolide B induces apoptosis in MCF-7 cells through inhibition of the PI3K/Akt/mTOR signaling pathway

Oncology Reports

Volumn 29, Issue 1, 2013, Pages 212-218

  Xu, Hui Yu ^a,b   Chen, Zhi Wei ^a,b   Hou, Jin Cai ^a   Du, Feng Xia ^a   Liu, Ji Cheng ^a  

^a QIQIHAR MEDICAL UNIVERSITY   (China)

^b HEILONGJIANG UNIVERSITY OF CHINESE MEDICINE   (China)

Author keywords

Apoptosis; Jolkinolide B; MCF 7; PI3K Akt mTOR

Indexed keywords

CYCLIN D1; CYCLIN E; DITERPENOID; INITIATION FACTOR 4E; JOLKINOLIDE B; MAMMALIAN TARGET OF RAPAMYCIN; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PLANT EXTRACT; PROTEIN KINASE B; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; BODY WEIGHT; BREAST CANCER; CANCER SIZE; CELL CYCLE; CELL PROLIFERATION; CELL STRAIN MCF 7; CELL STRUCTURE; CELL VIABILITY; CONTROLLED STUDY; DOWN REGULATION; DRUG MECHANISM; ENZYME INHIBITION; EUPHORBIA; EUPHORBIA FISCHERIANA; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; NONHUMAN; NUDE MOUSE; PLANT ROOT; PRIORITY JOURNAL; S PHASE CELL CYCLE CHECKPOINT; SIGNAL TRANSDUCTION; TRANSMISSION ELECTRON MICROSCOPY; UPREGULATION;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; BREAST NEOPLASMS; CELL CYCLE; CELL PROLIFERATION; DITERPENES; DRUGS, CHINESE HERBAL; FEMALE; FLOW CYTOMETRY; HUMANS; MICE; MICE, INBRED BALB C; PHOSPHATIDYLINOSITOL 3-KINASES; PLANT EXTRACTS; PROTO-ONCOGENE PROTEINS C-AKT; PTEN PHOSPHOHYDROLASE; SIGNAL TRANSDUCTION; TOR SERINE-THREONINE KINASES; TUMOR CELLS, CULTURED;

EID: 84872831035     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or.2012.2113     Document Type: Article

References (21)

1. Wang YB and Huang R: Diterpenoids from the roots of Euphorbia fischeriana. J Nat Prod 69: 967-970, 2006.
2. Liu WK and Ho JC: Jolkinolide B induces neuroendocrine differentiation of human prostate LNCaP cancer cell line. Biochem Pharmacol 63: 951-957, 2002.
3. Luo H and Wang A: Induction of apoptosis in K562 cells by jolkinolide B. Can J Physiol Pharmacol 84: 959-965, 2006.
4. Lin Y, Cui H, Xu H, Yue L, Xu H, Jiang L and Liu J: Jolkinolide B induces apoptosis in MDA-MB-231 cells through inhibition of the PI3K/Akt signaling pathway. Oncol Rep 27: 1976-1980, 2012.
5. Wang HB and Chu WJ: Diterpenoids from the roots of Euphorbia fischeriana. J Asian Nat Prod Res 12: 1038-1043, 2010.
6. Osaki M and Oshimura M: PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 9: 667-676, 2004.
7. Franke TF: PI3K/Akt: getting it right matters. Oncogene 27: 6473-6488, 2008.
8. Geering B and Cutillas PR: Regulation of class IA PI3Ks: is there a role for monomeric PI3K subunits. Biochem Soc Trans 35: 199-203, 2007.
9. Sussman M: 'AKT'ing lessons for stem cells: regulation of cardiac myocyte and progenitor cell proliferation. Trends Cardiovasc Med 17: 235-240, 2007.
10. Tsurutani J and Steinberg SM: Prognostic significance of clinical factors and Akt activation in patients with bronchioloalveolar carcinoma. Lung Cancer 55: 115-121, 2007.
11. Wu YT and Tan HL: Activation of the PI3K-Akt-mTOR signaling pathway promotes necrotic cell death via suppression of autophagy. Autophagy 5: 824-834, 2009.
12. Yuan ZQ and Sun M: Frequent activation of AKT2 and induction of apoptosis by inhibition of phosphoinositide-3-OH kinase/Akt pathway in human ovarian cancer. Oncogene 19: 2324-2330, 2000.
13. Achiwa Y and Haseqawa K: Regulation of phosphatidylinositol 3-kinase-Akt and the mitogen-activated protein kinase pathways by ursolic acid in human endometrial cancer cells. Biosci Biotechnol Biochem 71: 31-37, 2007.
14. Tang JM and He QY: Phosphorylated Akt overexpression and loss of PTEN expression in non-small cell lung cancer confers poor prognosis. Lung Cancer 51: 181-191, 2006.
15. Coffey JC and Wang JH: Phosphoinositide 3 kinase accelerates postoperative tumor growth by inhibiting apoptosis and enhancing resistance to chemotherapy-induced apoptosis. Novel role for an old enemy. J Biol Chem 280: 20968-20977, 2005.
16. Huang S and Houghton PJ: Targeting mTOR signaling for cancer therapy. Curr Opin Pharmacol 3: 371-377, 2003.
17. Zhou X and Tan M: Activation of the Akt/mammalian target of Rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clin Cancer Res 10: 6779-6788, 2004.
18. Asnaghi L, Bruno P, Priulla M, et al: mTOR: a protein kinase switching between life and death. Pharmacol Res 50: 545-549, 2004.
19. Coleman LJ and Peter MB: Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer 100: 1393-1399, 2009.
20. Bonifazi P and D'Angelo C: Intranasally delivered siRNA targeting PI3K/Akt/mTOR inflammatory pathways protects from aspergillosis. Mucosal Immunol 3: 193-206, 2010.
21. Madlener S and Saiko P: Multifactorial anticancer effects of digalloyl-resveratrol encompass apoptosis, cell-cycle arrest, and inhibition of lymph endothelial gap formation in vitro. Br J Cancer 102: 1361-1370. 2010.